As we know, there are two main classes of SARM, real SARM, selective androgen receptor modulators, and selective modulators of other receptors, which are classified as SARM.
MK677 has a special role here, it acts more like a peptide, so some people classify MK677 as a peptide.
MK677, a selective auxin-releasing peptide receptor agonist and growth hormone secretagogues, mimics the GH-stimulating effects of the endogenous hormone Ghrelin by increasing the secretion of several hormones, including GH and IGF-1, and consistently elevating plasma levels of these hormones without affecting cortisol levels. After a single oral administration of MK677, IGF-1 levels remained elevated for up to 24 hours.
GH is growth hormone, also known as HGH (Human Growth Hormone), is a peptide Hormone that stimulates Growth, cell reproduction and cell regeneration in humans and other animals. When GH is used in Bodybuilding, it is used as an anabolic agent to improve Bodybuilder performance.
IGF-1 is insulin-like growth factor-1 , also known as growth regulator, is mainly synthesized by the liver, with insulin-like structure and activity, can promote growth and development, regulate glucose metabolism, inhibit protein decomposition.
Igf-1 is produced by GH by stimulating the liver, and GH acts on bones and muscles mainly through IGF-1 in vivo. IGF-1 production is mainly dependent on GH, which is a downstream product of GH. If GH secretion is insufficient, IGF-1 is definitely insufficient.
IGF-1 is an index to detect the function of GH-IGF-1 axis. Compared with the characteristics of growth hormone GH's pulsed secretion and short half-life (about 10-20 minutes), IGF-1 is more stable in the blood and less affected by day and night fluctuations. Therefore, the concentration of IGF-1 in the blood is usually detected to determine whether GH is deficient.
MK677 has been shown to maintain GH-IGF-1 axis activation and increase lean body mass, increasing muscle mass and bone mineral density. It is also being investigated as a potential treatment for GH deficiency in children and the elderly and is currently in preclinical development.
Ghrp-6 is the first growth hormone-releasing peptide developed, and MK-677 is derived from its molecule.
Ghrp-6 and GHRP-2 are the most famous growth hormone-releasing peptides (GHRP). They also act by activating the auxin releasing peptide receptor, which stimulates the production of growth hormone in the body. However, GHRP-6 and GHRP-2 have a short half-life and need to be used several times a day. Moreover, the peptide structure of GHRP-6 and GHRP-2 makes them injectable only. Using multiple injections over the course of a day will leave marked marks on the skin.
Oral MK677 is more convenient to use, and the half-life of MK677 is longer. The frequency of use is once a day, which further improves the user's feeling.
The combination of SARMs and peptide, MK677, is also about to be used as a new treatment for GH deficiency. Feel free to contact us for more information.